Carisma Therapeutics

Carisma Therapeutics

  • Founded: 2017
  • Location: Philadelphia, PA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Solid tumors
  • Drug types: ONC
  • Lead product: CT-0508
  • Product link:
  • Funding: $12M B Mar 2021; $47M B Jan 2021; $53M A Jul 2018

job board

Short description:

CAR Macrophage Immunotherapy

Drug notes:

CT-0525 Clin0 solid tumors; CT-1119 Clin0 solid tumors; CT-0729 RD prostate cancer; undisclosed RD oncology

Long description:

Carisma Therapeutics is developing novel chimeric antigen receptor (CAR) macrophage technology to treat solid tumors. Engineering T cells with CARs has shown great advances in the treatment of hematologic malignancies, but such results have not been translated to solid tumors. Macrophages are a key component of the immune system that eat cancer cells from solid tumors. Carisma is engineering macrophages with CARs to redirect their activity towards tumor cells to provide long-term anti-tumor immunity. Carisma’s lead candidate, CT-0508, is an ex vivo gene-modified autologous therapy to treat HER2 solid tumors in Phase 1 development. Carisma is also working on allogeneic CAR-Macrophages that would provide an off-the-shelf product enabling more patients to benefit from their cell therapies.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy